Phase 2 N=310 Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Fibromyalgia
Primary: Change in the Mean Numerical Rating Scale (NRS) Score — -1.26; -1.47; -1.23 units on a scale — p=0.539
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Primary: Number of Participants With Stable, Decreased, or Increased PSA Doubling Times (PSADT) — 7; 2; 17 Participants
Phase 2 N=974 Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 12 — 0.013; 0.013; 0.014; 0.021 Liter — p=0.628
Phase 2 N=228 Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)
Diabetic Peripheral Neuropathic Pain
Primary: Pain Intensity Numeric Rating Scale (NRS) Score — -2.01; -2.27 units on a scale — p=0.704
Phase 2 N=59 Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Advanced Epithelial Ovarian · Recurrent Epithelial Ovarian · Fallopian Tube
Primary: Overall Response Rate — 1.7 percentage of participants with response
Phase 2 N=95 FX-322 in Adults With Stable Sensorineural Hearing Loss
Sensorineural Hearing Loss · Noise Induced Hearing Loss · Sudden Sensorineural Hearing Loss
Primary: Word Recognition in Quiet — 23.8; 16.7; 15.8; 18.8 Percent — p=0.068
Phase 2 N=20 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 5 Percentage of participants
Phase 2 N=25 Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Graft Rejection — 3 Participants
Phase 2 N=308 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
Primary: Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) — 10; 19; 14; 16 Participants — p=0.001
Phase 2 N=307 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
B-cell Malignancies · Colorectal Cancer (CRC) · Head and Neck Cancer
Primary: Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=26 Medication Development in Alcoholism: Suvorexant Versus Placebo
Alcohol Use Disorder (AUD)
Primary: Visual Analogue Scale (VAS) of Craving Severity: 2 Arms — 2.38; 1.44 score on a scale
Phase 2 N=92 Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction (HFpEF) (INABLE-Training)
Heart Failure
Primary: Change in Peak Rate of Oxygen (VO2) — 0.85; 0.70 ml/min/kg — p=0.770
Phase 2 N=33 Higher Doses of Botulinum Toxin in the Treatment of Gummy Smile
Smiling · Botulinum Toxins, Type A
Primary: Anterior Gingival Exposure (GE) 4 Weeks Post-injection — 3.6; 3.0 mm
Phase 2 N=52 A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
Giant Cell Arteritis
Primary: Percentage of Participants in Sustained Remission Until Week 28 — 19; 6 Participants
Phase 2 N=136 Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8 · Stage IVA Lung Cancer AJCC v8
Primary: Overall Survival (OS) — 11.6; 14.5 months — p=0.05